These findings suggest that EGCG’s suppression of the ET-1/ETAR autocrine loop may contribute to its anti-angiogenic and anti-invasive activities in ovarian cancer (Spinella et al., 2006). This evidence concerns the gene EDN1 and ovarian cancer.